Figure 2.

Validation of the MCI subgroups using fluid biomarker and cognitive data

Subjects in the MCI-AD and MCI-CN groups were rated as Amyloid (A) and p-tau (T), positive or negative, based on the CSF A $\beta$₄₂, and p-tau₁₈₁ biomarkers. Pie charts depict the biomarker score combinations in the MCI-AD (A) and MCI-CN (B) subgroups. These score distributions were significantly different between the two subgroups. Bar plots show differences in CDR-SB scores (C), CSF A $\beta$₄₂ (D), and CSF p-tau₁₈₁ (E). Bar graphs depict means $\pm$ SEs. AD, Alzheimer’s disease; CN, cognitively normal; MCI, mild cognitive impairment; CDR-SB, clinical dementia rating sum of boxes. ∗∗∗p < 0.001.